OPTIMIZERx Corporation Announces SampleMD(TM) Update
29 März 2011 - 5:06PM
Marketwired
OPTIMIZERx Corporation (OTCBB: OPRX) announced news relating to its
4Q 2010 launch of SampleMD -- its proprietary technology that
provides physicians a more efficient alternative to storing drug
samples by printing and electronically distributing prescription
trial vouchers, co-pay coupons and other patient information right
from their computers.
Pharmaceutical manufacturers contracted with SampleMD include
Merck & Co., Inc., Novartis Pharmaceuticals Corporation,
Genentech Inc., Abbott Laboratories, Boehringer Ingelheim
Pharmaceuticals, Inc., Bayer HealthCare Pharmaceuticals Inc.,
Sunovion Pharmaceuticals Inc. and Warner Chilcott Company LLC.
Additionally, the Company is in various stages of contractual
development with other leading pharmaceutical and biotech companies
and is now leveraging its equity partner Physicians Interactive LLC
to promote SampleMD through their highly established sales
force.
The Company is very pleased by the number of blue chip companies
who have recognized and signed up for SampleMD as a new way to
reach more physicians at point of care. However, the company has
recognized delays associated with extensive legal and compliance
reviews that are commonly associated with innovative technology
which provides new promotional processes. In response, the internal
account team is working to streamline the approval process to fully
ramp up promotional and revenue maximization.
Utilization of SampleMD within its initial rollout phase has
already generated promotion and distribution of over 16,000
vouchers and co-pay coupons since its launch, with almost 5,000 in
March alone and a redemption rate of 18% -- more than three times
the industry average. We expect these numbers to dramatically
escalate as we expand the number of participating brand
manufacturers and fully ramp up our network of participating
prescribers and health systems.
SampleMD's integration within Allscripts, the nation's largest
ePrescribing provider, EMR platforms provides access to over
100,000 providers, right at point of ePrescribing, in addition to
our leading health systems like Emory, Carilion, St. Barnabas and
Ochsner whom are using SampleMD as their exclusive alternative to
traditional drug samples.
The Company is also pursuing integration within other
ePrescribing and Electronic Health Records enterprise companies who
can provide an even larger base of healthcare providers. The
company's goal is to become the standard in delivering patient
savings and support right at the most critical time: when the
doctor is prescribing.
"With almost 200 million prescriptions electronically prescribed
this year -- and that number is expecting to double in each of the
next few years -- integration of SampleMD's eVouchers and
promotional services will provide us the potential for huge
growth," added David Harrell, Chairman and Founder of OptimizeRx,
"We have proven SampleMD's ability to help the manufacturer
increase product utilization while enabling doctors to help their
patients better afford and stay on the medicines they need."
For more information about SampleMD, please go to
www.samplemd.com.
About OPTIMIZERx Corporation
OPTIMIZERx Corp. provides unique consumer and physician
platforms to help patients better afford and comply with their
medicines and healthcare products, while offering pharmaceutical
and healthcare companies effective ways to expand patient
awareness, access and adherence to their brands. For more
information, please go to www.optimizerxcorp.com.
This press release contains forward-looking statements within
the definition of Section 27A of the Securities Act of 1933, as
amended and such section 21E of the Securities Act of 1934,
amended. These forward-looking statements should not be used to
make an investment decision. The words 'estimate,' 'possible' and
'seeking' and similar expressions identify forward-looking
statements, which speak only as to the date the statement was made.
The company undertakes no obligation to publicly update or revise
any forward-looking statements, whether because of new information,
future events, or otherwise. Forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot
be predicted, or quantified. Future events and actual results could
differ materially from those set forth in, contemplated by, or
underlying the forward-looking statements. The risks and
uncertainties to which forward-looking statements are subject
include, but are not limited to, the effect of government
regulation, competition and other material risks.
Company contact: Dave Lester CEO Optimizerx Corporation Inc.
248-651-6568 Email Contact
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jul 2023 bis Jul 2024